Azienda Ospedaliera S Giovanni Addolorata — Clinical Trial Site

37 Registered trials

19 Currently recruiting

Organisation

Azienda Ospedaliera S Giovanni Addolorata

Location

Rome, Italy

Identifier

ORG-100030771

Address

Via Merulana 143, 00185, Italy

Departments

Cardio Thoracic Vascular Department
DIPARTIMENTO SPECIALITÀ
DIPARTIMENTO SPECIALITÀ - UOC EMATOLOGIA
N/A
Oncologia
Oncologia Medica
Oncology
Reparto di Oncologia Medica
S.C. Ematologia - AO San Giovanni Addolorata
Sensory Organs
U.O.C. Oncologia
Unità Clinica di Fase I di Oncologia, Ematologia, Medicina Nucleare
Unità Operativa Complessa Oncologia
UOC CARDIOLOGIA D'URGENZA E UTIC
UOC Ematologia
UOC Gastroenterologia Endoscopia Digestiva
UOC Oncologia
UOC Oncology
UON Oncologia
UON Oncology
UOSD Terapia Antalgica

Clinical trials at this site (37)

Search interface

Phase II, clinical trial, to evaluate OS in two cohorts in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiot… Pending

2024-520081-65-00 NSCLC non-small cell lung cancer 4
Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations Pending

2025-520676-26-00 Non-small cell lung cancer (NSCLC) 4
A clinical study of new treatments for non-small cell lung cancer (MK-3475-01J) Recruiting

2025-521939-36-00 Participants with KRAS G12C-Mutant, Advanced or Metasta 4 2026-03-03
Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting

2025-521775-31-00 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutatio 5 2025-11-12
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w… Recruiting

2023-507853-13-00 Ulcerative Colitis 4 2025-02-25
Letrozole for Estrogen/Progesterone Receptor positive low-grade serous Epithelial ovarian cancer. A randomized phase III trial. LEPRE Trial Recruiting

2024-516874-31-00 Patients with a low-grade serous epithelial carcinoma o 5 2024-12-10
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting

2023-505749-14-00 c-Met overexpressing EGFR wildtype non-squamous non-sma 5 2022-03-20
A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) s… Recruiting

2024-518223-29-00 Advanced or metastatic untreated EGFR mutation positive 4 2020-03-10
Effects of ziltivekimab on coronary atherosclerotic burden in patients with acute myocardial infarction Recruiting

2024-520364-34-00 Acute myocardial infarction 5 2026-02-23
Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting

2024-515658-26-00 Unresectable or Metastatic HER2 overexpressing and PD-L 5 2026-01-21
A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007) Recruiting

2024-514500-14-00 Participants with KRAS G12C-Mutant, Advanced or Metasta 5 2025-12-15
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03
Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting

2024-514465-18-00 Advanced or Metastatic Non-Squamous NSCLC 9 2025-04-23
COLchicine and Thiamine in Heart Failure due to Ischemic Heart Disease (COLT-HF) Recruiting

2023-506675-96-00 Heart Failure 5 2025-01-23
PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRES… Recruiting

2023-506632-32-00 Metastatic colorectal cancer 5 2024-10-28
Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting

2023-510128-66-00 Participants with treatment-naïve metastatic squamous N 5 2024-09-02
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Recruiting

2022-502046-28-00 HER2-Positive, PIK3CA Mutated, Locally Advanced or Meta 5 2023-12-22
Phase III trial comparing local radiotherapy alone or with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial. Recruiting

2022-502775-29-01 Early stage Follicular Lymphoma 5 2023-12-14
The study is aimed at evaluating the feasibility of a hypomethylating treatment combined with hematopoietic stem cell transplantation in com… Recruiting

2023-510515-19-00 Higher-risk-myelodysplastic syndromes 5 2020-11-27
Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting

2023-510433-29-00 Favorable-intermediate-risk Acute Myeloid Leukemia 5 2020-09-24
Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-sm… Recruiting

2024-517200-10-00 Advanced non-small-cell lung cancer 4 2020-01-31
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL… Ended

2024-520050-38-00 Extensive stage small cell lung cancer (ES-SCLC). 5 2025-09-18
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC Ended

2024-516051-40-00 Small Cell Lung Cancer (SCLC) 4 2025-06-10
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended

2022-502669-14-00 Small cell lung cancer (SCLC) 5 2023-12-18